• Gryphon Login
  • MyCourses
  • Alumni
  • UCLA Health
  • Contact Us
Immunology

The Immunology, Inflammation, Infection, and Transplantation Research Theme (I3T)

Immunology
  • About
    • I3T Scientific Retreat
    • Immunology Postings
    • Overview
    • Leadership
    • Seminar Series
    • Spotlights
    • Immunology Postings
    • NIH-NIAID Consortium
    • Leadership
    • Seed Grant Awardees
    • Seminar Series
    • Spotlights
  • Immunology Research
    • Cancer Immunotherapy
    • Gene Therapy
    • Human Immune System Generation
    • Mechanobiology: Manipulating Cells and Tissues
  • Inflammation Research
    • Enhancing Immune Responses
    • Immunometabolism
    • Rheumatoid Arthritis
    • Transcriptional Cascades
  • Infection Research
    • Cryo-Electron Microscopy
    • International Public Health
    • Novel Anti-Infectives
    • Understanding Bacteria
  • Transplantation Research
    • Limb Transplantation
    • Organ Rejuvenation
    • Chronic Transplant Rejection
    • Transplant Education
  • Annual I3T Scientific Retreat
    • I3T Scientific Retreat 2018
  • UCLA Research Overview
  • Support Science
  • Gryphon Login
  • MyCourses
  • Alumni
  • UCLA Health
  • Contact Us

The Immunology, Inflammation, Infection, and Transplantation Research Theme (I3T)

Cancer Immunotherapy

  1. Home
  2. Immunology
  3. Immunology Research
  4. Cancer Immunotherapy

How can we get the immune system to cure cancer?

Share this

Antoni Ribas, MD, PhD
Director, Parker Institute for Cancer Immunotherapy Center at UCLA

Groundbreaking Interventions

Dr. Antoni Ribas develops groundbreaking immunotherapies, interventions that mobilize the immune system to fight cancer. By studying the cellular mechanisms driving—or inhibiting—an immune response to cancer, Dr. Ribas uncovers techniques to activate our natural defenses. 

Dr. Ribas’s discoveries have helped many patients fight cancer when nothing else worked.

Giving T Cells a "Green Light" to Fight Cancer

To allow T cells to fight cancer, Dr. Ribas tried blocking the programmed death-1 (PD-1) protein, a receptor cancer manipulates to evade immune response. 

He found that pembrolizimab—a drug developed by Merck to block PD-1—helped many patients fight their cancer. Read more in PD-1 Blockade Induces Responses by Inhibiting Adaptive Immune Resistance, published in Nature.

However, PD-1 blockade did not help all patients, and Dr. Ribas wanted to know why.

  • Pembrolizimab worked best when T cells had flocked to the tumor site, giving PD-1 blockade plenty of “fighters” to release. Read more in High Response Rate to PD-1 Blockade in Desmoplastic Melanomas, published in Nature.
  • Pembrolizimab failed when T cells ignored the tumor site, leaving PD-1 blockade with no “fighters” to release. Read more in Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma, published in the New England Journal of Medicine.

Bolstering Cancer Immunotherapies with Oncolytic Viruses

Dr. Ribas combined pembrolizimab with an oncolytic virus, injected at the tumor site. He believed the virus—a foreign invader—would lure T cells toward cancer tumors and boost the efficacy of PD-1 blockade.

The combined therapy increased T cells at tumor sites and stimulated a complete response in 33% of patients. Read more in Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy, the first phase 1 clinical trial report ever published in Cell.

With his sights set on optimizing cancer immunotherapy, Dr. Ribas plans to learn as much as he can by testing new treatments, including adoptive cell transfer therapy, and investigating the underlying immune system mechanisms that render treatments effective or ineffective.

The Future of Cancer Immunotherapy

Dr. Ribas wants to uncover the limits and potentials of the human immune system in the fight against cancer, a pursuit rooted in scientific understanding. When it comes to cancer, Dr. Ribas believes we can always know more about getting the immune system to fight back.

"Our progress did not happen by chance; it happened by understanding science, understanding the immune system, and turning that understanding into treatments."
- Dr. Antoni Ribas

Parker Institue for Cancer Immunotherapy

Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest Follow us on Flickr Follow us on Sharecare
Top 10 U.S. Medical Schools
  • Giving
  • Contact Us
  • Diversity
  • Emergency
  • Maps & Directions
  • Publications
  • Directory
  • Report Misconduct
  • Volunteer
  • Biomed Library
  • Newsroom
  • Smoke-Free
  • Sitemap
  • Terms of Use
  • Report Broken Links
Top 10 U.S. Medical Schools
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest Follow us on Flickr Follow us on Sharecare